HHS said Friday the company will use the funds to conduct large-scale production and Phase 3 trials of the experimental AZD7442 combo drug to help prevent or treat SARS-CoV-2 infections.
The biopharmaceutical firm licensed the two antibodies from Vanderbilt University and extended the compounds' duration of action using a proprietary technology.
According to HHS, the antiviral cocktail is intended to neutralize the novel coronavirus and reduce its ability to infect cells in the human body.
The federal government plans to widely distribute AZD7442 if the product receives approval from the Food and Drug Administration as part of Operation Warp Speed.
AeroVironment has tapped Robert “Rob” Smith as executive vice president and chief operating officer. Smith’s appointment, which will become official April 13, underscores…
GreyNoise Intelligence has launched Command and Control Detection, a new intelligence module designed to identify active cyber compromises using outbound…
BigBear.ai has named Jo Ann Bjornson as chief human resources officer and Alex Thompson as chief corporate affairs officer. The new leadership appointments…
